Prediction model for mortality after intracranial hemorrhage in patients with leukemia

Farshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, Jianqin Shan, Farhad Ravandi, Jorge Cortes, Jeffrey Weinberg, Elias Jabbour, Stefan Faderl, William Wierda, Deborah Thomas, Susan O'Brien, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Intracranial hemorrhage (ICH) is associated with great morbidity and mortality in patients with acute leukemia. We identified 118 patients with ICH from a total of 2,421 patient with leukemia who were treated at our institution between 2005-2009, and assessed the prognostic factors for mortality in the ICH cohort. Median age at time of ICH was 58 years, 49% were male, and 60% had acute myeloid leukemia. The relative incidence of ICH was highest in patients with chronic myeloid leukemia in blast crisis (12.1%). Mental status changes were the most common symptom which prompted work-up for ICH. Median survival for all patients after onset of ICH was 20 days. In multivariate analyses, four clinical characteristics were identified as independent adverse factors for mortality in patients with ICH: albumin <3.5 g/dL, lactate dehydrogenase (LDH) >835 U/L, age > 60 years, and relapsed disease status. Based on the number of risk factors, mortality after ICH was: 25% (0 risk factor), 47% (1), 78% (2), and >97% (3 or 4). In conclusion, patients with leukemia who develop ICH do not have universally poor outcomes, and a simple scoring system could serve to advise physicians and families of the prognosis and the potential benefit of aggressive treatment options.

Original languageEnglish (US)
Pages (from-to)546-549
Number of pages4
JournalAmerican Journal of Hematology
Volume86
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Prediction model for mortality after intracranial hemorrhage in patients with leukemia'. Together they form a unique fingerprint.

Cite this